×







We sell 100% Genuine & New Books only!

Handbook of HER2-Targeted Agents in Breast Cancer 2nd Edition 2016 Softbound at Meripustak

Handbook of HER2-Targeted Agents in Breast Cancer 2nd Edition 2016 Softbound by Ricardo H Alvarez, Javier Cortés, Mary Falzon, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart, Springer


  • Price: ₹ 6472.00/- [ 15.00% off ]

    Seller Price: ₹ 5501.00

Estimated Delivery Time : 4-5 Business Days

Sold By: Meripustak      Click for Bulk Order

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

We deliver across all postal codes in India

Orders Outside India


Add To Cart


Outside India Order Estimated Delivery Time
7-10 Business Days


  • We Deliver Across 100+ Countries

  • MeriPustak’s Books are 100% New & Original
  • General Information  
    Author(s)Ricardo H Alvarez, Javier Cortés, Mary Falzon, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart
    PublisherSpringer
    Edition2nd Edition
    ISBN9783319282145
    Pages110
    BindingSoftbound
    LanguageEnglish
    Publish YearMay 2016

    Description

    Springer Handbook of HER2-Targeted Agents in Breast Cancer 2nd Edition 2016 Softbound by Ricardo H Alvarez, Javier Cortés, Mary Falzon, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart

    This concise handbook provides oncologists and other healthcare providers with crucial updates in the field, including an updated review of the current understanding of the biology of the HER2 pathway, an overview of HER2-testing, and evidence-based discussions of available and emerging HER2-targeted treatment options. An essential clinical text for physicians that screen and treat patients with breast cancer and require an accessible, up-to-date survey of the dynamic treatment landscape. Introduction and background biology.- HER2 testing.- HER2-positive breast cancer: neoadjuvant and adjuvant therapy.- HER2-positive metastatic breast cancer: first-line treatment.- HER2-positive metastatic breast cancer: second-line treatment.- Emerging targeted agents for HER2-positive breast cancer.



    Book Successfully Added To Your Cart